Mbrace Therapeutics Raises $85 Million Series B Financing To Advance Oncology Pipeline Of Innovative Antibody Drug Conjugate Candidates

Nov 14, 2023•about 2 years ago

Amount Raised

$85 Million

Round Type

series b

San DiegoMedicalTherapeuticsPharmaceuticalBiotechnologyHealth Care

Investors

Alta PartnersVenrockCowen Healthcare InvestmentsAvidity PartnersThe Rise FundTpg Life Sciences InnovationsTpg

Description

MBraceTM Therapeutics, Inc. (“MBrace”), a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, announced the completion of an $85 million Series B financing, bringing the company’s total raised to $110 million. Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.

Company Information

Company

MBrace Therapeutics

Location

San Diego, California, United States

About

MBrace is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer. MBrace develops innovative treatments for cancer patients by developing novel antibody-drug conjugates against targets identified using technology pioneered by its founders. MBrace is headquartered in San Diego, CA, with research facilities at The Thomas O. Daniel Research Incubator and Collaboration Center at Bristol Myers Squibb in Summit, NJ. For additional information, please visit MBrace’s website at http://www.mbracetrx.com.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends